Brown, Darron R.Castellsagué, XavierFerris, DaronGarland, Suzanne M.Huh, WarnerSteben, MarcWheeler, Cosette M.Saah, AlfredLuxembourg, AlainLi, SeVelicer, Christine2022-06-272022-06-272022-05-012666-6790https://hdl.handle.net/2445/187066Background: Estimates of the humoral immune response to incident human papillomavirus (HPV) infections are limited. Methods: In this post hoc analysis of 3875 women aged 16-23 years from a 4-valent HPV vaccine trial (NCT00092482), HPV seroprevalence on day 1 was measured with a 9-valent HPV (HPV 6/11/16/18/31/33/45/ 52/58) competitive Luminex immunoassay and compared with cervical/external genital HPV detection by po-lymerase chain reaction. In the control group, among women who were HPV DNA-negative on day 1, sero-conversion following initial HPV detection was estimated using Kaplan-Meier methods. Results: Type-specific HPV seropositivity among women with no day 1 cervical/external genital HPV detection was 0.6%-3.6%. Women with any 9-valent HPV (9vHPV) cervical/external genital detection (796/3875; 20.5%) had concordant seropositivity ranging from 13.4% (HPV 45) to 38.5% (HPV 6). Among women in the control group who were negative for all HPV types on day 1, seroconversion by month 30 after initial detection ranged from 29% (HPV 45) to 75% (HPV 16). Conclusions: Humoral immune response to HPV is variable and dynamic, depending on type-specific exposure. This longitudinal analysis provides insight into the relationship between incident infection and seropositivity.9 p.application/pdfengcc by-nc-nd (c) Brown, Darron R. et al, 2022http://creativecommons.org/licenses/by-nc-nd/3.0/es/Papil·lomavirusGenètica humanaPapillomavirusesHuman geneticsinfo:eu-repo/semantics/article2022-06-27info:eu-repo/semantics/openAccess35525430